Cervical Intraepithelial Neoplasia (CIN), Cervical cancer
Conditions
Interventions
Women who are eligible for the national cervical screening program receive an invitation to participate in this study. When women return a signed informed consent form, they will be randomized between
women in the control arm will be asked to perform additional self-sampling for hrHPV DNA testing. This cross-testing is performed to see if individual HPV results match between the self-sample and the
Sponsors
VU University Medical Center, Department of Pathology
Erasmus Medical Center, Department of Pathology
Radboud University Medical Center, Department of Gynaecology
National Institute for Public Health and the Environment (RIVM)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Women invited for the national screening program in 2015 (ages 30-60 years) 2. Women should reside in the regions covered by district health authorities of Noord-Holland, Flevoland, Utrecht, Zuid-Holland, Zeeland, Gelderland en Overijssel (in the Netherlands)
Exclusion criteria
Exclusion criteria: 1. Not in the population based screening program, i.e. ages under 30 years or over 60 years 2. Cervical smear in the past 12 months or under follow-up/treatment by gynaecologist 3. Current pregnancy 4. Hysterectomy, incl. cervix
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of CIN2+ and CIN3+ lesions in both study arms | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the cost-effectiveness between both study arms | — |
Contacts
Public ContactN.J. Polman
VU medisch centrum; Department of Pathology
Outcome results
None listed